» Articles » PMID: 12022599

Selection Criteria for Hepatic Resection in Patients with Large Hepatocellular Carcinoma Larger Than 10 Cm in Diameter

Overview
Journal J Am Coll Surg
Date 2002 May 23
PMID 12022599
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of hepatic resection for large hepatocellular carcinoma (HCC) larger than 10 cm remains unclear.

Study Design: Perioperative and longterm outcomes of 120 patients with HCC larger than 10 cm who underwent resection (group A) were compared with 368 patients with smaller HCC (group B). The prognostic factors in group A were analyzed.

Results: A higher proportion of patients underwent major hepatic resection in group A than in group B (90% versus 57.6%, p = 0.001), but the hospital mortality was similar (5.0% versus 4.6%, p = 0.874). Group A had worse longterm overall survival (median 18.8 months versus 62.8 months, p < 0.001) and disease-free survival (median 5.5 months versus 25.4 months, p < 0.001) than group B. Macroscopic residual tumor, macroscopic venous invasion, and multiple tumors were identified as independent prognostic factors in group A. The median survival of patients with residual tumor and those with curative resection was 7.7 months and 20.8 months, respectively. The median survival of patients with curative resection of solitary HCC larger than 10cm without macroscopic venous invasion was 38.0 months; that of patients with both macroscopic venous invasion and multiple tumors was only 10.5 months.

Conclusions: Hepatic resection is a safe and effective treatment for HCC larger than 10cm when liver function reserve is satisfactory and when curative resection can be expected. Patients with solitary HCC larger than 10cm without macroscopic venous invasion can enjoy longterm survival after surgery, and we propose hepatic resection as a standard treatment for this group of patients.

Citing Articles

Clinical features and prognostic factors of patients with inoperable hepatocellular carcinoma treated with chemotherapy: a population-based study.

Gao Y, Xu Y, Wang Y, Lu J, Guo J J Gastrointest Oncol. 2024; 15(3):1122-1140.

PMID: 38989427 PMC: 11231877. DOI: 10.21037/jgo-24-298.


Investigating the Influence of Preoperative Trans Arterial Embolization (TAE) and Predictive Potential of Circulating Tumor Cells (CTCs) in Prognosis of Hepatocellular Carcinoma.

Patkar S, Shetty O, Vyas K, Vengurlekar V, Kamble V, Shetty N J Clin Exp Hepatol. 2024; 14(6):101445.

PMID: 38975607 PMC: 11222936. DOI: 10.1016/j.jceh.2024.101445.


Prognostic significance of MRI features in patients with solitary large hepatocellular carcinoma following surgical resection.

Gu K, Min J, Lee J, Shin J, Jeong W, Kim Y Eur Radiol. 2024; 34(11):7002-7012.

PMID: 38767659 DOI: 10.1007/s00330-024-10780-x.


Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis.

Wen Y, Lu L, Mei J, Ling Y, Guan R, Lin W J Hepatocell Carcinoma. 2024; 11:665-678.

PMID: 38596593 PMC: 11001557. DOI: 10.2147/JHC.S453250.


Nomogram for predicting overall survival in patients with large (>5 cm) hepatocellular carcinoma based on real-world practice.

Kim N, Yu J, Park H, Hong J, Lim H, Goh M J Liver Cancer. 2023; 23(2):350-361.

PMID: 37670423 PMC: 10565549. DOI: 10.17998/jlc.2023.08.10.